<?xml version="1.0"?>
<ichicsr lang="en">
  <ichicsrmessageheader>
    <messagetype>ICSR</messagetype>
    <messageformatversion>2.1</messageformatversion>
    <messageformatrelease>1.0</messageformatrelease>
    <messagenumb>2014-12</messagenumb>
    <messagesenderidentifier>FDA CDER</messagesenderidentifier>
    <messagereceiveridentifier>Public Use</messagereceiveridentifier>
    <messagedateformat>204</messagedateformat>
    <messagedate>20141216061225</messagedate>
  </ichicsrmessageheader>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>10007919</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140313</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140526</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>PHEH2014US005047</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>NOVARTIS</duplicatesource>
      <duplicatenumb>PHEH2014US005047</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>COUNTRY NOT SPECIFIED</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Bladder neoplasm</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Toxicity to various agents</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>GLEEVEC</medicinalproduct>
        <drugbatchnumb> F0228</drugbatchnumb>
        <drugauthorizationnumb>021588</drugauthorizationnumb>
        <drugstructuredosagenumb>400</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>400 MG, QD</drugdosagetext>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>COLON CANCER</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>GLEEVEC</medicinalproduct>
        <drugauthorizationnumb>021588</drugauthorizationnumb>
        <drugstructuredosagenumb>2</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugdosagetext>2 DF, DAILY</drugdosagetext>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>GASTRIC CANCER</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>10007953</safetyreportid>
    <primarysourcecountry>JP</primarysourcecountry>
    <occurcountry>JP</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140313</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140429</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>JP-JNJFOC-20140308109</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>JANSSEN</duplicatesource>
      <duplicatenumb>JP-JNJFOC-20140308109</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>JP</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientweight>40</patientweight>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Sudden death</reactionmeddrapt>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>REMINYL</medicinalproduct>
        <drugauthorizationnumb>021169</drugauthorizationnumb>
        <drugstructuredosagenumb>8</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosageform>TABLETS</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>DEMENTIA ALZHEIMER^S TYPE</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140307</drugstartdate>
        <drugrecurreadministration>2</drugrecurreadministration>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>10007959</safetyreportid>
    <primarysourcecountry>CA</primarysourcecountry>
    <occurcountry>CA</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140313</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140521</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>PHHY2014CA028793</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>SANDOZ</duplicatesource>
      <duplicatenumb>PHHY2014CA028793</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>CA</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Renal pain</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Eye swelling</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Eye discharge</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Epistaxis</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Choking</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Vision blurred</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Upper-airway cough syndrome</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Nasopharyngitis</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Nausea</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Drug effect incomplete</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DILTIAZEM SANDOZ </medicinalproduct>
        <drugauthorizationnumb>91022</drugauthorizationnumb>
        <drugstructuredosagenumb>120</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>120 MG, UNK</drugdosagetext>
        <drugdosageform>CAPSULE</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>BLOOD PRESSURE</drugindication>
        <actiondrug>4</actiondrug>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>4</safetyreportversion>
    <safetyreportid>10008047</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140313</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140404</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-JNJFOC-20140304686</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>JANSSEN</duplicatesource>
      <duplicatenumb>US-JNJFOC-20140304686</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Haemorrhage</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>XARELTO</medicinalproduct>
        <drugbatchnumb> UNKNOWN</drugbatchnumb>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>CEREBROVASCULAR ACCIDENT PROPHYLAXIS</drugindication>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>2</drugrecurreadministration>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>XARELTO</medicinalproduct>
        <drugbatchnumb> UNKNOWN</drugbatchnumb>
        <drugauthorizationnumb>202439</drugauthorizationnumb>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>ATRIAL FIBRILLATION</drugindication>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>2</drugrecurreadministration>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>3</safetyreportversion>
    <safetyreportid>10008071</safetyreportid>
    <primarysourcecountry>IT</primarysourcecountry>
    <occurcountry>IT</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140313</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140529</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>IT-MYLANLABS-2014S1004855</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>MYLAN</duplicatesource>
      <duplicatenumb>IT-MYLANLABS-2014S1004855</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>IT</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>86</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Drug abuse</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Hypokalaemia</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Oedema peripheral</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Renal failure acute</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Overdose</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>FUROSEMIDE</medicinalproduct>
        <drugauthorizationnumb>018487</drugauthorizationnumb>
        <drugstructuredosagenumb>5</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>5 DF DAILY</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>URINE OUTPUT DECREASED</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>201312</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20140219</drugenddate>
        <actiondrug>1</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>KARVEZIDE</medicinalproduct>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>HYPERTENSION</drugindication>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20140219</drugenddate>
        <actiondrug>1</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CARDIOASPIRIN</medicinalproduct>
        <drugindication>PRODUCT USED FOR UNKNOWN INDICATION</drugindication>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>10007994</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140313</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140625</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-PFIZER INC-2014071817</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>PFIZER</duplicatesource>
      <duplicatenumb>US-PFIZER INC-2014071817</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Drug ineffective</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Drug intolerance</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>VENLAFAXINE HCL</medicinalproduct>
        <drugauthorizationnumb>020699</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <actiondrug>1</actiondrug>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>6</safetyreportversion>
    <safetyreportid>10008012</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnesslifethreatening>1</seriousnesslifethreatening>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessdisabling>1</seriousnessdisabling>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140313</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140410</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-JNJFOC-20140306823</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>JANSSEN</duplicatesource>
      <duplicatenumb>US-JNJFOC-20140306823</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>2</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>79</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>68.5</patientweight>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Basal ganglia haemorrhage</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Demyelination</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Cerebral amyloid angiopathy</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>XARELTO</medicinalproduct>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>ATRIAL FIBRILLATION</drugindication>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>XARELTO</medicinalproduct>
        <drugauthorizationnumb>202439</drugauthorizationnumb>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>CEREBROVASCULAR ACCIDENT PROPHYLAXIS</drugindication>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>VITAMINE E</medicinalproduct>
        <drugdosageform>Unspecified</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>7</safetyreportversion>
    <safetyreportid>10008014</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnesslifethreatening>1</seriousnesslifethreatening>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140313</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140410</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-JNJFOC-20140306509</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>JANSSEN</duplicatesource>
      <duplicatenumb>US-JNJFOC-20140306509</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>2</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>89</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>122.47</patientweight>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Gastrointestinal haemorrhage</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Haemoglobin decreased</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Incorrect dose administered</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>XARELTO</medicinalproduct>
        <drugstructuredosagenumb>15</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>CEREBROVASCULAR ACCIDENT PROPHYLAXIS</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20130909</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20131108</drugenddate>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>2</drugrecurreadministration>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>XARELTO</medicinalproduct>
        <drugauthorizationnumb>202439</drugauthorizationnumb>
        <drugstructuredosagenumb>15</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>ATRIAL FIBRILLATION</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20130909</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20131108</drugenddate>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>2</drugrecurreadministration>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ESCITALOPRAM</medicinalproduct>
        <drugstructuredosagenumb>5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosageform>Unspecified</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ALUMINIUM W/MAGNESIUM HYDROXIDE/SIMETICONE</medicinalproduct>
        <drugdosagetext>400-400-40 MG/5ML DOSE EVERY 6 HOURS AS NECESSARY</drugdosagetext>
        <drugdosageform>Unspecified</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>DYSPEPSIA</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>FUROSEMIDE</medicinalproduct>
        <drugstructuredosagenumb>60</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosageform>Unspecified</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ACETAMINOPHEN</medicinalproduct>
        <drugstructuredosagenumb>500</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>AS NECESSARY</drugdosagetext>
        <drugdosageform>Capsules</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>PYREXIA</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ACETAMINOPHEN</medicinalproduct>
        <drugstructuredosagenumb>500</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>AS NECESSARY</drugdosagetext>
        <drugdosageform>Capsules</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>PAIN</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PROMETHAZINE</medicinalproduct>
        <drugstructuredosagenumb>25</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>6</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugdosagetext>AS NECESSARY</drugdosagetext>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>VOMITING</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PROMETHAZINE</medicinalproduct>
        <drugstructuredosagenumb>25</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>6</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugdosagetext>AS NECESSARY</drugdosagetext>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>NAUSEA</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PANTOPRAZOLE</medicinalproduct>
        <drugstructuredosagenumb>40</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ALPRAZOLAM</medicinalproduct>
        <drugstructuredosagenumb>.25</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>3</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>AS NECESSARY</drugdosagetext>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>DEXTROMETHORPHAN/GUAIFENESIN</medicinalproduct>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>012</drugstructuredosageunit>
        <drugdosagetext>AS NECESSARY</drugdosagetext>
        <drugdosageform>Unspecified</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>COUGH</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>FERROUS SULFATE</medicinalproduct>
        <drugstructuredosagenumb>325</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>65 MG IRON</drugdosagetext>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>POTASSIUM CHLORIDE</medicinalproduct>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>029</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>3</safetyreportversion>
    <safetyreportid>10008026</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140313</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140505</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-JNJFOC-20140303979</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>JANSSEN</duplicatesource>
      <duplicatenumb>US-JNJFOC-20140303979</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>42.119</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>64.41</patientweight>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Drug withdrawal syndrome</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Product packaging quantity issue</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Feeling hot</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Drug dose omission</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Therapeutic response decreased</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DURAGESIC</medicinalproduct>
        <drugbatchnumb> 1304822P1;1304822P1 +MORE</drugbatchnumb>
        <drugdosagetext>25UG/HR+12.5UG/HR</drugdosagetext>
        <drugdosageform>Matrix Patch</drugdosageform>
        <drugadministrationroute>062</drugadministrationroute>
        <drugindication>PAIN</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140213</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20140302</drugenddate>
        <actiondrug>4</actiondrug>
        <drugrecurreadministration>2</drugrecurreadministration>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DURAGESIC</medicinalproduct>
        <drugbatchnumb> 1304822P1;1304822P1 +MORE</drugbatchnumb>
        <drugauthorizationnumb>019813</drugauthorizationnumb>
        <drugdosageform>Matrix Patch</drugdosageform>
        <drugadministrationroute>062</drugadministrationroute>
        <drugindication>PAIN</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140310</drugstartdate>
        <actiondrug>4</actiondrug>
        <drugrecurreadministration>2</drugrecurreadministration>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>3</safetyreportversion>
    <safetyreportid>10008030</safetyreportid>
    <primarysourcecountry>KR</primarysourcecountry>
    <occurcountry>KR</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>2</reporttype>
    <serious>2</serious>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140313</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140515</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>KR-JNJFOC-20140304550</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>JANSSEN</duplicatesource>
      <duplicatenumb>KR-JNJFOC-20140304550</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>KR</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>36.14</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Liver function test abnormal</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>STELARA</medicinalproduct>
        <drugstructuredosagenumb>45</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosageform>Liquid</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>PSORIASIS</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20130514</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20130514</drugenddate>
        <actiondrug>4</actiondrug>
        <drugrecurreadministration>2</drugrecurreadministration>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>STELARA</medicinalproduct>
        <drugauthorizationnumb>125261</drugauthorizationnumb>
        <drugstructuredosagenumb>45</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosageform>Liquid</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>PSORIASIS</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20130419</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20130419</drugenddate>
        <actiondrug>4</actiondrug>
        <drugrecurreadministration>2</drugrecurreadministration>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PYRIDOXINE</medicinalproduct>
        <drugstructuredosagenumb>50</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>LATENT TUBERCULOSIS</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20130405</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20131004</drugenddate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>YUHANZID</medicinalproduct>
        <drugstructuredosagenumb>300</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosageform>Unspecified</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>LATENT TUBERCULOSIS</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20130405</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20131004</drugenddate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PRIMALAN</medicinalproduct>
        <drugstructuredosagenumb>5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosageform>Unspecified</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>PSORIASIS</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20121024</drugstartdate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>DAIVOBET</medicinalproduct>
        <drugdosageform>Unspecified</drugdosageform>
        <drugadministrationroute>061</drugadministrationroute>
        <drugindication>PSORIASIS</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20130604</drugstartdate>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>10008039</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140313</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140613</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-PFIZER INC-2014068423</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>PFIZER</duplicatesource>
      <duplicatenumb>US-PFIZER INC-2014068423</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>33</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Type 2 diabetes mellitus</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>LIPITOR</medicinalproduct>
        <drugauthorizationnumb>020702</drugauthorizationnumb>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>20 MG, 1X/DAY</drugdosagetext>
        <drugdosageform>FILM-COATED TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>LOW DENSITY LIPOPROTEIN INCREASED</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>200910</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>201302</drugenddate>
        <actiondrug>5</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>LIPITOR</medicinalproduct>
        <drugauthorizationnumb>020702</drugauthorizationnumb>
        <drugdosageform>FILM-COATED TABLET</drugdosageform>
        <drugindication>CARDIOVASCULAR EVENT PROPHYLAXIS</drugindication>
        <actiondrug>5</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ATORVASTATIN CALCIUM</medicinalproduct>
        <drugauthorizationnumb>020702</drugauthorizationnumb>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>20 MG, 1X/DAY</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>BLOOD CHOLESTEROL INCREASED</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2012</drugstartdate>
        <drugenddateformat>602</drugenddateformat>
        <drugenddate>2013</drugenddate>
        <actiondrug>5</actiondrug>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>10007531</safetyreportid>
    <primarysourcecountry>JP</primarysourcecountry>
    <occurcountry>JP</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140313</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140416</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>JP-EISAI INC-E2020-13643-SOL-JP</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>EISAI</duplicatesource>
      <duplicatenumb>JP-EISAI INC-E2020-13643-SOL-JP</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>JP</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>80.148</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Haemoptysis</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Pneumonia aspiration</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Anaemia</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ARICEPT</medicinalproduct>
        <drugauthorizationnumb>020690</drugauthorizationnumb>
        <drugstructuredosagenumb>3</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>DEMENTIA ALZHEIMER^S TYPE</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20131105</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20131118</drugenddate>
        <actiondrug>1</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ARICEPT</medicinalproduct>
        <drugauthorizationnumb>020690</drugauthorizationnumb>
        <drugstructuredosagenumb>5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20131119</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20131203</drugenddate>
        <actiondrug>1</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>YOKUKANSAN</medicinalproduct>
        <drugindication>DEMENTIA ALZHEIMER^S TYPE</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>AMOBAN</medicinalproduct>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>AMLODIPINE OD</medicinalproduct>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>SLOW-K</medicinalproduct>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>MAGNESIUM OXIDE</medicinalproduct>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>3</safetyreportversion>
    <safetyreportid>10007547</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140313</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140625</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-PFIZER INC-2014068403</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>PFIZER</duplicatesource>
      <duplicatenumb>US-PFIZER INC-2014068403</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>59</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Type 2 diabetes mellitus</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>LIPITOR</medicinalproduct>
        <drugauthorizationnumb>020702</drugauthorizationnumb>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>20 MG, DAILY</drugdosagetext>
        <drugdosageform>FILM-COATED TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>LOW DENSITY LIPOPROTEIN INCREASED</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>200401</drugstartdate>
        <actiondrug>4</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>LIPITOR</medicinalproduct>
        <drugauthorizationnumb>020702</drugauthorizationnumb>
        <drugdosageform>FILM-COATED TABLET</drugdosageform>
        <drugindication>CARDIOVASCULAR EVENT PROPHYLAXIS</drugindication>
        <actiondrug>4</actiondrug>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>10040770</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140327</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140522</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-JNJFOC-20140309311</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>JANSSEN</duplicatesource>
      <duplicatenumb>US-JNJFOC-20140309311</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>48.049</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>61.69</patientweight>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Deafness</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Blindness</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Convulsion</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Mental disorder</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Insomnia</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Immune system disorder</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Multi-organ failure</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Adverse event</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Dyskinesia</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Skin mass</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Blister</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Bone disorder</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Abnormal loss of weight</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Drug ineffective</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Drug ineffective</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Burning sensation</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Skin exfoliation</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Deformity</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Influenza like illness</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Panic attack</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Plague</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Impaired driving ability</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Bedridden</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Feeling abnormal</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Stress</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>LEVAQUIN</medicinalproduct>
        <drugbatchnumb> UNKNOWN</drugbatchnumb>
        <drugdosageform>TABLETS</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>SINUS DISORDER</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2008</drugstartdate>
        <drugenddateformat>602</drugenddateformat>
        <drugenddate>2008</drugenddate>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>LEVAQUIN</medicinalproduct>
        <drugbatchnumb> UNKNOWN</drugbatchnumb>
        <drugauthorizationnumb>020634</drugauthorizationnumb>
        <drugdosageform>TABLETS</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>EAR PAIN</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2008</drugstartdate>
        <drugenddateformat>602</drugenddateformat>
        <drugenddate>2008</drugenddate>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>LEVAQUIN</medicinalproduct>
        <drugdosageform>SOLUTION</drugdosageform>
        <drugadministrationroute>042</drugadministrationroute>
        <drugindication>SINUS DISORDER</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2008</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>200811</drugenddate>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>2</drugrecurreadministration>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>LEVAQUIN</medicinalproduct>
        <drugauthorizationnumb>020635</drugauthorizationnumb>
        <drugdosageform>SOLUTION</drugdosageform>
        <drugadministrationroute>042</drugadministrationroute>
        <drugindication>EAR PAIN</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2008</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>200811</drugenddate>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>2</drugrecurreadministration>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>10041017</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140327</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140515</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-BAYER-2014-042948</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>BAYER</duplicatesource>
      <duplicatenumb>US-BAYER-2014-042948</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>23</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>49.89</patientweight>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Uterine perforation</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Injury</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Emotional distress</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Psychological trauma</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Depression</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Anxiety</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Device issue</reactionmeddrapt>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>MIRENA</medicinalproduct>
        <drugbatchnumb> 83381A</drugbatchnumb>
        <drugauthorizationnumb>021225</drugauthorizationnumb>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>004</drugstructuredosageunit>
        <drugdosagetext>20 MCG/24HR, CONT</drugdosagetext>
        <drugdosageform>Intrauterine delivery system</drugdosageform>
        <drugadministrationroute>015</drugadministrationroute>
        <drugindication>CONTRACEPTION</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20090320</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20120317</drugenddate>
        <actiondrug>1</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>MIRENA</medicinalproduct>
        <drugauthorizationnumb>021225</drugauthorizationnumb>
        <drugdosageform>Intrauterine delivery system</drugdosageform>
        <drugindication>MENORRHAGIA</drugindication>
        <actiondrug>1</actiondrug>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>10041026</safetyreportid>
    <primarysourcecountry>JP</primarysourcecountry>
    <occurcountry>JP</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140327</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140418</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>JP-ASTRAZENECA-2014SE20537</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>ASTRAZENECA</duplicatesource>
      <duplicatenumb>JP-ASTRAZENECA-2014SE20537</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>JP</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>14</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Aplasia pure red cell</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Cytokine storm</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Histiocytosis haematophagic</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>MEROPEN</medicinalproduct>
        <drugdosageform>SOLUTION FOR INJECTION</drugdosageform>
        <drugadministrationroute>042</drugadministrationroute>
        <actiondrug>5</actiondrug>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>3</safetyreportversion>
    <safetyreportid>10041212</safetyreportid>
    <primarysourcecountry>JP</primarysourcecountry>
    <occurcountry>JP</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140327</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140428</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>JP-SA-2014SA035428</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>AVENTIS</duplicatesource>
      <duplicatenumb>JP-SA-2014SA035428</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>JP</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>51</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Electrocardiogram QT prolonged</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Hypomagnesaemia</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>LASIX</medicinalproduct>
        <drugbatchnumb> UNKNOWN</drugbatchnumb>
        <drugauthorizationnumb>016273</drugauthorizationnumb>
        <drugstructuredosagenumb>40</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>ASCITES</drugindication>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20140319</drugenddate>
        <actiondrug>1</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>GLUCOBAY</medicinalproduct>
        <drugstructuredosagenumb>100</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>3</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>DIABETES MELLITUS</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>JANUVIA</medicinalproduct>
        <drugstructuredosagenumb>50</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>DIABETES MELLITUS</drugindication>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>3</safetyreportversion>
    <safetyreportid>10041223</safetyreportid>
    <primarysourcecountry>IN</primarysourcecountry>
    <occurcountry>IN</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>2</reporttype>
    <serious>2</serious>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140327</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140501</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>PHHY2014IN035712</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>NOVARTIS</duplicatesource>
      <duplicatenumb>PHHY2014IN035712</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>COUNTRY NOT SPECIFIED</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>67</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Neurological symptom</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Tremor</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Skin disorder</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Gait disturbance</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Arthralgia</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Drug ineffective</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ACLASTA</medicinalproduct>
        <drugauthorizationnumb>021817</drugauthorizationnumb>
        <drugstructuredosagenumb>5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>5 MG/ 100 ML/ YEAR</drugdosagetext>
        <drugdosageform>SOLUTION FOR INJECTION</drugdosageform>
        <drugadministrationroute>042</drugadministrationroute>
        <drugindication>OSTEOPOROSIS</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20130318</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>4</safetyreportversion>
    <safetyreportid>10041233</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140327</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140424</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-INCYTE CORPORATION-2014IN000727</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>INCYTE</duplicatesource>
      <duplicatenumb>US-INCYTE CORPORATION-2014IN000727</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>74.73</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>73.47</patientweight>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Disease progression</reactionmeddrapt>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Splenic rupture</reactionmeddrapt>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Shock</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Dyspnoea</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Renal failure acute</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Respiratory failure</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Multi-organ failure</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Hyperkalaemia</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Metabolic acidosis</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Lactic acidosis</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Fluid retention</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Haemoglobin decreased</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Abdominal distension</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Abdominal discomfort</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Splenomegaly</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>JAKAFI</medicinalproduct>
        <drugauthorizationnumb>202192</drugauthorizationnumb>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugcumulativedosagenumb>10540</drugcumulativedosagenumb>
        <drugcumulativedosageunit>003</drugcumulativedosageunit>
        <drugdosagetext>20 MG, BID</drugdosagetext>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20111216</drugstartdate>
        <actiondrug>2</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>JAKAFI</medicinalproduct>
        <drugbatchnumb> AA5271G</drugbatchnumb>
        <drugauthorizationnumb>202192</drugauthorizationnumb>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugcumulativedosagenumb>10540</drugcumulativedosagenumb>
        <drugcumulativedosageunit>003</drugcumulativedosageunit>
        <drugdosagetext>10 MG, BID</drugdosagetext>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20121010</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20140320</drugenddate>
        <actiondrug>2</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>AMLODIPINE</medicinalproduct>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CLOBETASOL</medicinalproduct>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>TRIAMCINOLONE</medicinalproduct>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>HYDROXYUREA</medicinalproduct>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>FORADIL</medicinalproduct>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>HYDROCORTISONE                     /00028602/</medicinalproduct>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CICLOPIROX</medicinalproduct>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>TERBINAFINE</medicinalproduct>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>HYDROCHLOROTHIAZIDE</medicinalproduct>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ARCAPTA</medicinalproduct>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>GENADUR</medicinalproduct>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>10041284</safetyreportid>
    <primarysourcecountry>GR</primarysourcecountry>
    <occurcountry>GR</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140327</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140404</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>GR-MERCK-1403GRC009600</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>MERCK</duplicatesource>
      <duplicatenumb>GR-MERCK-1403GRC009600</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>GR</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>60</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>67</patientweight>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Oropharyngeal pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Pyrexia</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Speech disorder</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>JANUVIA</medicinalproduct>
        <drugauthorizationnumb>021995</drugauthorizationnumb>
        <drugstructuredosagenumb>100</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>100 MG, QAM</drugdosagetext>
        <drugdosageform>FILM-COATED TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <actiondrug>4</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>GLUCOPHAGE</medicinalproduct>
        <drugdosagetext>TOTAL DAILY DOSE: 1/2 TABLET AT THE NOON</drugdosagetext>
        <drugdosageform>TABLET</drugdosageform>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>10041296</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140327</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140425</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-ALEXION PHARMACEUTICALS INC.-A201002036</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>ALEXION</duplicatesource>
      <duplicatenumb>US-ALEXION PHARMACEUTICALS INC.-A201002036</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Transfusion</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Abdominal pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>SOLIRIS</medicinalproduct>
        <drugauthorizationnumb>125166</drugauthorizationnumb>
        <drugdosageform>CONCENTRATE FOR SOLUTION FOR INFUSION</drugdosageform>
        <drugadministrationroute>042</drugadministrationroute>
        <drugindication>PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA</drugindication>
        <actiondrug>5</actiondrug>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>3</safetyreportversion>
    <safetyreportid>10041438</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140327</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140613</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-AMGEN-USASP2014020316</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>AMGEN</duplicatesource>
      <duplicatenumb>US-AMGEN-USASP2014020316</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>76</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Respiratory failure</reactionmeddrapt>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Chronic obstructive pulmonary disease</reactionmeddrapt>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PROLIA</medicinalproduct>
        <drugauthorizationnumb>125320</drugauthorizationnumb>
        <drugstructuredosagenumb>60</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>60 MG, Q6MO</drugdosagetext>
        <drugdosageform>SOLUTION FOR INJECTION</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>OSTEOPOROSIS POSTMENOPAUSAL</drugindication>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>10041486</safetyreportid>
    <primarysourcecountry>JP</primarysourcecountry>
    <occurcountry>JP</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140327</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140409</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>JP-AMGEN-JPNCT2014022039</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>AMGEN</duplicatesource>
      <duplicatenumb>JP-AMGEN-JPNCT2014022039</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>JP</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>70</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>62</patientweight>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Drowning</reactionmeddrapt>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Liver disorder</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Blood creatinine increased</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DENOSUMAB</medicinalproduct>
        <drugauthorizationnumb>125320</drugauthorizationnumb>
        <drugstructuredosagenumb>120</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>120 MG, UNK</drugdosagetext>
        <drugdosageform>SOLUTION FOR INJECTION</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>METASTASES TO BONE</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20130423</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20131022</drugenddate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PEMETREXED</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20130611</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20131023</drugenddate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ZOMETA</medicinalproduct>
        <drugstructuredosagenumb>4</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>4 MG, QD</drugdosagetext>
        <drugdosageform>INJECTION</drugdosageform>
        <drugadministrationroute>042</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20110328</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20130312</drugenddate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CALCICHEW</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>1 DF, QD</drugdosagetext>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20130423</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20130610</drugenddate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>DENOTAS</medicinalproduct>
        <drugstructuredosagenumb>2</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>2 DF, QD</drugdosagetext>
        <drugdosageform>CHEWABLE TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20130611</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20131023</drugenddate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CARBOPLATIN</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20061012</drugstartdate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PACLITAXEL</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20061012</drugstartdate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>IRESSA</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20080805</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20100216</drugenddate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>AFATINIB</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>201003</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20110323</drugenddate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>AMRUBICIN</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20110530</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20110728</drugenddate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>TS-1</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20110922</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20120320</drugenddate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>BEVACIZUMAB</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20110922</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20131023</drugenddate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>TARCEVA</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20120914</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20130528</drugenddate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>OXYCONTIN</medicinalproduct>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>10 MG, QD</drugdosagetext>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20120806</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20131023</drugenddate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>TAKEPRON</medicinalproduct>
        <drugstructuredosagenumb>15</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>15 MG, QD</drugdosagetext>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20121023</drugenddate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>LIPITOR</medicinalproduct>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>10 MG, QD</drugdosagetext>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20120508</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20131023</drugenddate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CELECOX</medicinalproduct>
        <drugstructuredosagenumb>200</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>200 MG, QD</drugdosagetext>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20120621</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20131023</drugenddate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>OLMETEC</medicinalproduct>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>20 MG, QD</drugdosagetext>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20121207</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20131023</drugenddate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>AMITIZA</medicinalproduct>
        <drugstructuredosagenumb>48</drugstructuredosagenumb>
        <drugstructuredosageunit>004</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>48 MUG, QD</drugdosagetext>
        <drugdosageform>CAPSULE</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20130219</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20131023</drugenddate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>YODEL-S</medicinalproduct>
        <drugstructuredosagenumb>160</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>160 MG, QD</drugdosagetext>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20120927</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20131023</drugenddate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PANVITAN                           /07504101/</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>002</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>1 G, QD</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20130514</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20131023</drugenddate>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>10041557</safetyreportid>
    <primarysourcecountry>DE</primarysourcecountry>
    <occurcountry>DE</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140327</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140417</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>DE-NOVOPROD-403774</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>NOVO NORDISK</duplicatesource>
      <duplicatenumb>DE-NOVOPROD-403774</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>DE</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>51</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>92</patientweight>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Pancreatic pseudocyst</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Metabolic disorder</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>VICTOZA</medicinalproduct>
        <drugbatchnumb> UNKNOWN</drugbatchnumb>
        <drugauthorizationnumb>022341</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>SOLUTION FOR INJECTION</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>TYPE 2 DIABETES MELLITUS</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>201005</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>201006</drugenddate>
        <actiondrug>1</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>VICTOZA</medicinalproduct>
        <drugbatchnumb> UNKNOWN</drugbatchnumb>
        <drugauthorizationnumb>022341</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>SOLUTION FOR INJECTION</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140113</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20140118</drugenddate>
        <actiondrug>1</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>METFORMIN</medicinalproduct>
        <drugbatchnumb> UNKNOWN</drugbatchnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>TYPE 2 DIABETES MELLITUS</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>201006</drugstartdate>
        <actiondrug>1</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>METFORMIN</medicinalproduct>
        <drugbatchnumb> UNKNOWN</drugbatchnumb>
        <drugstructuredosagenumb>500</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>500 MG, BID</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20140112</drugenddate>
        <actiondrug>1</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>METFORMIN</medicinalproduct>
        <drugbatchnumb> UNKNOWN</drugbatchnumb>
        <drugstructuredosagenumb>500</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>500 MG, BID</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140205</drugstartdate>
        <actiondrug>1</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>SITAGLIPTIN</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>TYPE 2 DIABETES MELLITUS</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>201006</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>201401</drugenddate>
        <actiondrug>1</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>NOVORAPID</medicinalproduct>
        <drugbatchnumb> UNKNOWN</drugbatchnumb>
        <drugstructuredosagenumb>52</drugstructuredosagenumb>
        <drugstructuredosageunit>025</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>52 IE, QD (24 IE- MORNING, 10 IE- MID DAY AND 18 IE - EVENING)</drugdosagetext>
        <drugdosageform>SOLUTION FOR INJECTION</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>TYPE 2 DIABETES MELLITUS</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140123</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20140204</drugenddate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>NOVORAPID</medicinalproduct>
        <drugbatchnumb> UNKNOWN</drugbatchnumb>
        <drugstructuredosagenumb>44</drugstructuredosagenumb>
        <drugstructuredosageunit>025</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>44 IE, QD (18 IE- MORNING, 10 IE- MID DAY AND 16 IE-EVENING)</drugdosagetext>
        <drugdosageform>SOLUTION FOR INJECTION</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140205</drugstartdate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>LEVEMIR</medicinalproduct>
        <drugbatchnumb> UNKNOWN</drugbatchnumb>
        <drugstructuredosagenumb>16</drugstructuredosagenumb>
        <drugstructuredosageunit>025</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>16 IE, QD (8 IE - MORNING AND 8 IE - EVENING)</drugdosagetext>
        <drugdosageform>SOLUTION FOR INJECTION</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>TYPE 2 DIABETES MELLITUS</drugindication>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20140204</drugenddate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>LEVEMIR</medicinalproduct>
        <drugbatchnumb> UNKNOWN</drugbatchnumb>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>025</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>20 IE, QD (10 IE - MORNING AND 10 IE- EVENING)</drugdosagetext>
        <drugdosageform>SOLUTION FOR INJECTION</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140205</drugstartdate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>L-THYROXIN</medicinalproduct>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>175 UG, QD</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>THYROID HORMONE REPLACEMENT THERAPY</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>RAMIPRIL</medicinalproduct>
        <drugstructuredosagenumb>5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>5 MG, BID</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>AMLODIPIN                          /00972401/</medicinalproduct>
        <drugstructuredosagenumb>5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>5 MG, QD</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>HCT</medicinalproduct>
        <drugdosagetext>25 MG, (0.5-0-0)</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>4</safetyreportversion>
    <safetyreportid>10041692</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140327</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140519</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-PFIZER INC-2014083456</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>PFIZER</duplicatesource>
      <duplicatenumb>US-PFIZER INC-2014083456</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>80</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>81.63</patientweight>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Extra dose administered</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Diarrhoea</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>JUNIOR STRENGTH ADVIL</medicinalproduct>
        <drugbatchnumb> F62368</drugbatchnumb>
        <drugauthorizationnumb>020267</drugauthorizationnumb>
        <drugstructuredosagenumb>2</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugdosagetext>2 TABLETS, EVERY 4-6 HOURS</drugdosagetext>
        <drugdosageform>TABLET</drugdosageform>
        <drugindication>PAIN</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140317</drugstartdate>
        <actiondrug>4</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>JUNIOR STRENGTH ADVIL</medicinalproduct>
        <drugauthorizationnumb>020267</drugauthorizationnumb>
        <drugstructuredosagenumb>4</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugdosagetext>4 TABLETS, EVERY 4-6 HOURS</drugdosagetext>
        <drugdosageform>TABLET</drugdosageform>
        <drugindication>SWELLING</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140318</drugstartdate>
        <actiondrug>4</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>JUNIOR STRENGTH ADVIL</medicinalproduct>
        <drugauthorizationnumb>020267</drugauthorizationnumb>
        <drugstructuredosagenumb>2</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugdosagetext>2 TABLETS, EVERY 4-6 HOURS</drugdosagetext>
        <drugdosageform>TABLET</drugdosageform>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140319</drugstartdate>
        <actiondrug>4</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>AMLODIPINE</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugindication>HYPERTENSION</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>LOSARTAN POTASSIUM</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugindication>HYPERTENSION</drugindication>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>3</safetyreportversion>
    <safetyreportid>10041702</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140327</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140404</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-PFIZER INC-2014083373</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>PFIZER</duplicatesource>
      <duplicatenumb>US-PFIZER INC-2014083373</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>63</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>90.7</patientweight>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Drug ineffective</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>LYRICA</medicinalproduct>
        <drugauthorizationnumb>021446</drugauthorizationnumb>
        <drugstructuredosagenumb>50</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>50 MG, 2X/DAY</drugdosagetext>
        <drugdosageform>CAPSULE, HARD</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>BACK PAIN</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2014</drugstartdate>
        <actiondrug>4</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>LYRICA</medicinalproduct>
        <drugauthorizationnumb>021446</drugauthorizationnumb>
        <drugstructuredosagenumb>75</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>75 MG, 2X/DAY</drugdosagetext>
        <drugdosageform>CAPSULE, HARD</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>PAIN IN EXTREMITY</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>201403</drugstartdate>
        <actiondrug>4</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ENALAPRIL</medicinalproduct>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>10 MG, 2X/DAY</drugdosagetext>
        <drugindication>HYPERTENSION</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ENALAPRIL</medicinalproduct>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>10 MG, UNK</drugdosagetext>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>VITAMIN B3</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>VITAMIN B12</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>DICLOFENAC</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>OMEGA 3</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>MAGNESIUM</medicinalproduct>
        <drugstructuredosagenumb>400</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>400 MG, UNK</drugdosagetext>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CO Q10</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>10041734</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140327</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140616</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-PFIZER INC-2014080605</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>PFIZER</duplicatesource>
      <duplicatenumb>US-PFIZER INC-2014080605</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>65</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Type 2 diabetes mellitus</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>LIPITOR</medicinalproduct>
        <drugauthorizationnumb>020702</drugauthorizationnumb>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>20 MG, UNK</drugdosagetext>
        <drugdosageform>FILM-COATED TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>LOW DENSITY LIPOPROTEIN INCREASED</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20050408</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20071008</drugenddate>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>LIPITOR</medicinalproduct>
        <drugauthorizationnumb>020702</drugauthorizationnumb>
        <drugdosageform>FILM-COATED TABLET</drugdosageform>
        <drugindication>CARDIOVASCULAR EVENT PROPHYLAXIS</drugindication>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>10041773</safetyreportid>
    <primarysourcecountry>GB</primarysourcecountry>
    <occurcountry>GB</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140327</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140507</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>GB-ACTAVIS-2014-05478</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>ACTAVIS</duplicatesource>
      <duplicatenumb>GB-ACTAVIS-2014-05478</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>GB</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>57</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Alanine aminotransferase increased</reactionmeddrapt>
        <reactionoutcome>4</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ACYCLOVIR (UNKNOWN)</medicinalproduct>
        <drugbatchnumb> UNCONFIRMED</drugbatchnumb>
        <drugauthorizationnumb>74738</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Unk</drugdosageform>
        <drugadministrationroute>042</drugadministrationroute>
        <drugindication>ENCEPHALITIS</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140220</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20140224</drugenddate>
        <actiondrug>1</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>CEFTRIAXONE (UNKNOWN)</medicinalproduct>
        <drugbatchnumb> UNCONFIRMED</drugbatchnumb>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>002</drugstructuredosageunit>
        <drugdosagetext>1 G, UNKNOWN; VIALS</drugdosagetext>
        <drugdosageform>Unk</drugdosageform>
        <drugadministrationroute>042</drugadministrationroute>
        <drugindication>ENCEPHALITIS</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140220</drugstartdate>
        <actiondrug>1</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PARACETAMOL  (UNKNOWN)</medicinalproduct>
        <drugbatchnumb> UNCONFIRMED</drugbatchnumb>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>002</drugstructuredosageunit>
        <drugdosagetext>1 G, QID; STARTED THIS ADMISSION</drugdosagetext>
        <drugdosageform>Unk</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>ENCEPHALITIS</drugindication>
        <actiondrug>1</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ASPIRIN</medicinalproduct>
        <drugstructuredosagenumb>75</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>75 MG, DAILY</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>PRODUCT USED FOR UNKNOWN INDICATION</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CHLORDIAZEPOXIDE</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>PRODUCT USED FOR UNKNOWN INDICATION</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140217</drugstartdate>
        <actiondrug>2</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>FRAGMIN</medicinalproduct>
        <drugstructuredosagenumb>5000</drugstructuredosagenumb>
        <drugstructuredosageunit>025</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>5000 IU, DAILY; 5000IU/0.2ML</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>PRODUCT USED FOR UNKNOWN INDICATION</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>HALOPERIDOL</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>1 MG, PRN; TWICE DAILY WHEN REQUIRED</drugdosagetext>
        <drugadministrationroute>040</drugadministrationroute>
        <drugindication>PRODUCT USED FOR UNKNOWN INDICATION</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140217</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20140223</drugenddate>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>LAMOTRIGINE</medicinalproduct>
        <drugstructuredosagenumb>450</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>450 MG, BID</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>PRODUCT USED FOR UNKNOWN INDICATION</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>LEVETIRACETAM</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugdosagetext>1 DF= 500 MG EVERY MORNING AND 1 G AT NIGHT</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>PRODUCT USED FOR UNKNOWN INDICATION</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>LORAZEPAM</medicinalproduct>
        <drugstructuredosagenumb>.5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>0.5 MG, QID</drugdosagetext>
        <drugadministrationroute>040</drugadministrationroute>
        <drugindication>PRODUCT USED FOR UNKNOWN INDICATION</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140224</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>NIMOTOP</medicinalproduct>
        <drugstructuredosagenumb>60</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>4</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugdosagetext>60 MG, Q4H</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>PRODUCT USED FOR UNKNOWN INDICATION</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>OMEPRAZOLE</medicinalproduct>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>20 MG, DAILY</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>PRODUCT USED FOR UNKNOWN INDICATION</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140216</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PABRINEX                           /01800301/</medicinalproduct>
        <drugstructuredosagenumb>2</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>3</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>2 DF, TID; ASCORBIC ACID + NICOTINAMIDE}ASCORBIC ACID 500MG/2ML / NICOTINAMIDE 160MG/2ML AMPOULES</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>PRODUCT USED FOR UNKNOWN INDICATION</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140216</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20140219</drugenddate>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>SANDO K                            /00209301/</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>1 DF, BID; POTASSIUM BICARBONATE + POTASSIUM CHLORIDE}POTASSIUM CHLORIDE (POTASSIUM 12MMOL)</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>PRODUCT USED FOR UNKNOWN INDICATION</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140224</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>6</safetyreportversion>
    <safetyreportid>10041777</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140327</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140423</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-JNJFOC-20140313720</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>JANSSEN</duplicatesource>
      <duplicatenumb>US-JNJFOC-20140313720</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Paralysis</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Haemorrhage intracranial</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Cerebrovascular accident</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Treatment noncompliance</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>XARELTO</medicinalproduct>
        <drugdosagetext>ABOUT 1 YEAR</drugdosagetext>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>ATRIAL FIBRILLATION</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>XARELTO</medicinalproduct>
        <drugauthorizationnumb>202439</drugauthorizationnumb>
        <drugdosagetext>ABOUT 1 YEAR</drugdosagetext>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>CEREBROVASCULAR ACCIDENT PROPHYLAXIS</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>10041823</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140327</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140408</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-BAXTER-2014BAX015443</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>BAXTER</duplicatesource>
      <duplicatenumb>US-BAXTER-2014BAX015443</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>46</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Diarrhoea</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Nausea</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DIANEAL LOW CALCIUM</medicinalproduct>
        <drugauthorizationnumb>17512080</drugauthorizationnumb>
        <drugdosageform>SOLUTION FOR PERITONEAL DIALYSIS</drugdosageform>
        <drugadministrationroute>033</drugadministrationroute>
        <drugindication>PERITONEAL DIALYSIS</drugindication>
        <actiondrug>4</actiondrug>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>10044286</safetyreportid>
    <primarysourcecountry>CH</primarysourcecountry>
    <occurcountry>CH</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140328</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140414</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>CH-BEH-2014041528</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>CSL BEHRING</duplicatesource>
      <duplicatenumb>CH-BEH-2014041528</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>CH</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>76</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Drug ineffective for unapproved indication</reactionmeddrapt>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>HAEMATE P</medicinalproduct>
        <drugauthorizationnumb>103960</drugauthorizationnumb>
        <drugstructuredosagenumb>2000</drugstructuredosagenumb>
        <drugstructuredosageunit>025</drugstructuredosageunit>
        <drugdosagetext>CUMULATIVE DOSE AT END OP (OPERATION)</drugdosagetext>
        <drugindication>COAGULOPATHY</drugindication>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BERIPLEX P/N</medicinalproduct>
        <drugstructuredosagenumb>2000</drugstructuredosagenumb>
        <drugstructuredosageunit>025</drugstructuredosageunit>
        <drugdosagetext>CUMULATIVE DOSE AT 1 H POST CPB (CARDIOPULMONARY BYPASS): 2000 IU</drugdosagetext>
        <drugindication>COAGULOPATHY</drugindication>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BERIPLEX P/N</medicinalproduct>
        <drugstructuredosagenumb>8000</drugstructuredosagenumb>
        <drugstructuredosageunit>025</drugstructuredosageunit>
        <drugdosagetext>CUMULATIVE DOSE AT END OP (OPERATION): 10000IU</drugdosagetext>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BERIPLEX P/N</medicinalproduct>
        <drugstructuredosagenumb>3000</drugstructuredosagenumb>
        <drugstructuredosageunit>025</drugstructuredosageunit>
        <drugdosagetext>CUMULATIVE DOSE AT START IHD (INTERMITTENT HAEMODIAFILTRATION): 13000 IU</drugdosagetext>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BERIPLEX P/N</medicinalproduct>
        <drugstructuredosagenumb>2000</drugstructuredosagenumb>
        <drugstructuredosageunit>025</drugstructuredosageunit>
        <drugdosagetext>CUMULATIVE DOSE AT IHD (INTERMITTENT HAEMODIAFILTRATION) 1 H: 15000 IU</drugdosagetext>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BERIPLEX P/N</medicinalproduct>
        <drugstructuredosagenumb>2000</drugstructuredosagenumb>
        <drugstructuredosageunit>025</drugstructuredosageunit>
        <drugdosagetext>CUMULATIVE DOSE AT IHD (INTERMITTENT HAEMODIAFILTRATION) 2 H AND EXITUS: 17000 IU</drugdosagetext>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>FIBROGAMMIN P</medicinalproduct>
        <drugstructuredosagenumb>1250</drugstructuredosagenumb>
        <drugstructuredosageunit>025</drugstructuredosageunit>
        <drugdosagetext>CUMULATIVE DOSE AT 1 H POST CPB (CARDIOPULMONARY BYPASS): 1250 IU</drugdosagetext>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>FIBROGAMMIN P</medicinalproduct>
        <drugstructuredosagenumb>3750</drugstructuredosagenumb>
        <drugstructuredosageunit>025</drugstructuredosageunit>
        <drugdosagetext>CUMULATIVE DOSE AT END OP (OPERATION): 5000 IU</drugdosagetext>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>FIBROGAMMIN P</medicinalproduct>
        <drugstructuredosagenumb>1250</drugstructuredosagenumb>
        <drugstructuredosageunit>025</drugstructuredosageunit>
        <drugdosagetext>CUMULATIVE DOSE AT START IHD (INTERMITTENT HAEMODIAFILTRATION): 6250 IU</drugdosagetext>
        <drugindication>COAGULOPATHY</drugindication>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>FIBROGAMMIN P</medicinalproduct>
        <drugstructuredosagenumb>1250</drugstructuredosagenumb>
        <drugstructuredosageunit>025</drugstructuredosageunit>
        <drugdosagetext>CUMULATIVE DOSE AT IHD (INTERMITTENT HAEMODIAFILTRATION) 2 H AND EXITUS: 7500 IU</drugdosagetext>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>HAEMOCOMPLETTAN P</medicinalproduct>
        <drugstructuredosagenumb>8</drugstructuredosagenumb>
        <drugstructuredosageunit>002</drugstructuredosageunit>
        <drugdosagetext>CUMULATIVE DOSE AT 1 H POST CPB (CARDIOPULMONARY BYPASS): 8 G</drugdosagetext>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>HAEMOCOMPLETTAN P</medicinalproduct>
        <drugstructuredosagenumb>28</drugstructuredosagenumb>
        <drugstructuredosageunit>002</drugstructuredosageunit>
        <drugdosagetext>CUMULATIVE DOSE AT END OP (OPERATION): 36 G</drugdosagetext>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>HAEMOCOMPLETTAN P</medicinalproduct>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>002</drugstructuredosageunit>
        <drugdosagetext>CUMULATIVE DOSE AT START IHD (INTERMITTENT HAEMODIAFILTRATION): 46 G</drugdosagetext>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>HAEMOCOMPLETTAN P</medicinalproduct>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>002</drugstructuredosageunit>
        <drugdosagetext>CUMULATIVE DOSE AT IHD (INTERMITTENT HAEMODIAFILTRATION) 1 H: 56 G</drugdosagetext>
        <drugindication>COAGULOPATHY</drugindication>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>HAEMOCOMPLETTAN P</medicinalproduct>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>002</drugstructuredosageunit>
        <drugdosagetext>CUMULATIVE DOSE AT IHD (INTERMITTENT HAEMODIAFILTRATION) 2 H: 66 G</drugdosagetext>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>HAEMOCOMPLETTAN P</medicinalproduct>
        <drugstructuredosagenumb>2</drugstructuredosagenumb>
        <drugstructuredosageunit>002</drugstructuredosageunit>
        <drugdosagetext>CUMULATIVE DOSE AT EXITUS: 68 G</drugdosagetext>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DESMOPRESSIN</medicinalproduct>
        <drugstructuredosagenumb>40</drugstructuredosagenumb>
        <drugstructuredosageunit>004</drugstructuredosageunit>
        <drugdosagetext>CUMULATIVE DOSE AT END OP (OPERATION): 40 MCG</drugdosagetext>
        <drugindication>COAGULOPATHY</drugindication>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RFVIIA</medicinalproduct>
        <drugstructuredosagenumb>3</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>CUMULATIVE DOSE AT END OP (OPERATION): 3 MG</drugdosagetext>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RFVIIA</medicinalproduct>
        <drugstructuredosagenumb>2</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>CUMULATIVE DOSE AT START IHD (INTERMITTENT HAEMODIAFILTRATION): 5 MG</drugdosagetext>
        <drugindication>COAGULOPATHY</drugindication>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RFVIIA</medicinalproduct>
        <drugstructuredosagenumb>2</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>CUMULATIVE DOSE AT EXITUS: 7 MG</drugdosagetext>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PRB</medicinalproduct>
        <drugdosagetext>CUMULATIVE DOSE AT EXITUS: 55 UNITS</drugdosagetext>
        <drugindication>COAGULOPATHY</drugindication>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>FFP</medicinalproduct>
        <drugdosagetext>CUMULATIVE DOSE AT EXITUS: 36 UNITS</drugdosagetext>
        <drugindication>COAGULOPATHY</drugindication>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PLATELETS</medicinalproduct>
        <drugdosagetext>CUMULATIVE DOSE AT EXITUS: 20 UNITS</drugdosagetext>
        <drugindication>COAGULOPATHY</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>NEBIVOLOL</medicinalproduct>
        <drugstructuredosagenumb>1.25</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PERINDOPRIL</medicinalproduct>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>DABIGATRAN</medicinalproduct>
        <drugstructuredosagenumb>150</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugindication>ATRIAL FIBRILLATION</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>HEPARIN</medicinalproduct>
        <drugstructuredosagenumb>300</drugstructuredosagenumb>
        <drugstructuredosageunit>028</drugstructuredosageunit>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>TRANEXAMIC ACID</medicinalproduct>
        <drugstructuredosagenumb>30</drugstructuredosagenumb>
        <drugstructuredosageunit>007</drugstructuredosageunit>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PROTAMINE</medicinalproduct>
        <drugstructuredosagenumb>300</drugstructuredosagenumb>
        <drugstructuredosageunit>028</drugstructuredosageunit>
        <drugindication>HEPARIN NEUTRALISATION THERAPY</drugindication>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>10042751</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140327</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140417</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-BAXTER-2014BAX015275</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>BAXTER</duplicatesource>
      <duplicatenumb>US-BAXTER-2014BAX015275</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Peritonitis</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Peritoneal dialysis complication</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DIANEAL LOW CALCIUM</medicinalproduct>
        <drugauthorizationnumb>17512080</drugauthorizationnumb>
        <drugdosageform>SOLUTION FOR PERITONEAL DIALYSIS</drugdosageform>
        <drugadministrationroute>033</drugadministrationroute>
        <drugindication>PERITONEAL DIALYSIS</drugindication>
        <actiondrug>4</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>EXTRANEAL</medicinalproduct>
        <drugauthorizationnumb>021321</drugauthorizationnumb>
        <drugdosageform>SOLUTION FOR PERITONEAL DIALYSIS</drugdosageform>
        <drugadministrationroute>033</drugadministrationroute>
        <drugindication>PERITONEAL DIALYSIS</drugindication>
        <actiondrug>4</actiondrug>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>10041832</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140327</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140410</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-BAXTER-2014BAX015182</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>BAXTER</duplicatesource>
      <duplicatenumb>US-BAXTER-2014BAX015182</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Infection</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Peritonitis bacterial</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DIANEAL LOW CALCIUM</medicinalproduct>
        <drugauthorizationnumb>17512076</drugauthorizationnumb>
        <drugstructuredosagenumb>1.7</drugstructuredosagenumb>
        <drugstructuredosageunit>011</drugstructuredosageunit>
        <drugdosageform>SOLUTION FOR PERITONEAL DIALYSIS</drugdosageform>
        <drugadministrationroute>033</drugadministrationroute>
        <drugindication>PERITONEAL DIALYSIS</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20050913</drugstartdate>
        <actiondrug>4</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DIANEAL LOW CALCIUM</medicinalproduct>
        <drugauthorizationnumb>17512076</drugauthorizationnumb>
        <drugstructuredosagenumb>500</drugstructuredosagenumb>
        <drugstructuredosageunit>012</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosageform>SOLUTION FOR PERITONEAL DIALYSIS</drugdosageform>
        <drugadministrationroute>033</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20050913</drugstartdate>
        <actiondrug>4</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DIANEAL LOW CALCIUM</medicinalproduct>
        <drugauthorizationnumb>17512080</drugauthorizationnumb>
        <drugstructuredosagenumb>1.7</drugstructuredosagenumb>
        <drugstructuredosageunit>011</drugstructuredosageunit>
        <drugdosageform>SOLUTION FOR PERITONEAL DIALYSIS</drugdosageform>
        <drugadministrationroute>033</drugadministrationroute>
        <drugindication>PERITONEAL DIALYSIS</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20050913</drugstartdate>
        <actiondrug>4</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DIANEAL LOW CALCIUM</medicinalproduct>
        <drugauthorizationnumb>17512080</drugauthorizationnumb>
        <drugstructuredosagenumb>500</drugstructuredosagenumb>
        <drugstructuredosageunit>012</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosageform>SOLUTION FOR PERITONEAL DIALYSIS</drugdosageform>
        <drugadministrationroute>033</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20050913</drugstartdate>
        <actiondrug>4</actiondrug>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>10041836</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140327</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140401</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-BAXTER-2014BAX015422</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>BAXTER</duplicatesource>
      <duplicatenumb>US-BAXTER-2014BAX015422</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>90</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Urinary tract infection</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DIANEAL LOW CALCIUM</medicinalproduct>
        <drugauthorizationnumb>17512076</drugauthorizationnumb>
        <drugdosageform>SOLUTION FOR PERITONEAL DIALYSIS</drugdosageform>
        <drugadministrationroute>033</drugadministrationroute>
        <drugindication>RENAL FAILURE CHRONIC</drugindication>
        <actiondrug>4</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DIANEAL LOW CALCIUM</medicinalproduct>
        <drugauthorizationnumb>17512080</drugauthorizationnumb>
        <drugdosageform>SOLUTION FOR PERITONEAL DIALYSIS</drugdosageform>
        <drugadministrationroute>033</drugadministrationroute>
        <drugindication>RENAL FAILURE CHRONIC</drugindication>
        <actiondrug>4</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DIANEAL LOW CALCIUM</medicinalproduct>
        <drugauthorizationnumb>17512080</drugauthorizationnumb>
        <drugdosageform>SOLUTION FOR PERITONEAL DIALYSIS</drugdosageform>
        <drugadministrationroute>033</drugadministrationroute>
        <drugindication>RENAL FAILURE CHRONIC</drugindication>
        <actiondrug>4</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>EXTRANEAL</medicinalproduct>
        <drugauthorizationnumb>021321</drugauthorizationnumb>
        <drugdosageform>SOLUTION FOR PERITONEAL DIALYSIS</drugdosageform>
        <drugadministrationroute>033</drugadministrationroute>
        <drugindication>PERITONEAL DIALYSIS</drugindication>
        <actiondrug>4</actiondrug>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>10041851</safetyreportid>
    <primarysourcecountry>JP</primarysourcecountry>
    <occurcountry>JP</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140327</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140404</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>JP-BAXTER-2014BAX015087</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>BAXTER</duplicatesource>
      <duplicatenumb>JP-BAXTER-2014BAX015087</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>JP</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientweight>45</patientweight>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Cardiac failure chronic</reactionmeddrapt>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Marasmus</reactionmeddrapt>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DIANEAL-N PD-4 1.5 PD SOLUTION</medicinalproduct>
        <drugauthorizationnumb>17512076</drugauthorizationnumb>
        <drugstructuredosagenumb>2.5</drugstructuredosagenumb>
        <drugstructuredosageunit>011</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosageform>SOLUTION FOR PERITONEAL DIALYSIS</drugdosageform>
        <drugadministrationroute>033</drugadministrationroute>
        <drugindication>RENAL FAILURE CHRONIC</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>201106</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20140321</drugenddate>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DIANEAL-N PD-4 1.5 PD SOLUTION</medicinalproduct>
        <drugauthorizationnumb>17512076</drugauthorizationnumb>
        <drugstructuredosagenumb>5</drugstructuredosagenumb>
        <drugstructuredosageunit>011</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosageform>SOLUTION FOR PERITONEAL DIALYSIS</drugdosageform>
        <drugadministrationroute>033</drugadministrationroute>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>201106</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20140321</drugenddate>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>10041858</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140327</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140514</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-BAXTER-2014BAX015030</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>BAXTER</duplicatesource>
      <duplicatenumb>US-BAXTER-2014BAX015030</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>44</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Pancreatitis</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DIANEAL LOW CALCIUM</medicinalproduct>
        <drugdosageform>SOLUTION FOR PERITONEAL DIALYSIS</drugdosageform>
        <drugadministrationroute>033</drugadministrationroute>
        <drugindication>PERITONEAL DIALYSIS</drugindication>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DIANEAL LOW CALCIUM</medicinalproduct>
        <drugauthorizationnumb>020183</drugauthorizationnumb>
        <drugdosageform>SOLUTION FOR PERITONEAL DIALYSIS</drugdosageform>
        <drugadministrationroute>033</drugadministrationroute>
        <drugindication>PERITONEAL DIALYSIS</drugindication>
        <actiondrug>4</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DIANEAL LOW CALCIUM (ULTRABAG)</medicinalproduct>
        <drugauthorizationnumb>17512076</drugauthorizationnumb>
        <drugdosageform>SOLUTION FOR PERITONEAL DIALYSIS</drugdosageform>
        <drugadministrationroute>033</drugadministrationroute>
        <drugindication>PERITONEAL DIALYSIS</drugindication>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DIANEAL LOW CALCIUM (ULTRABAG)</medicinalproduct>
        <drugauthorizationnumb>17512080</drugauthorizationnumb>
        <drugdosageform>SOLUTION FOR PERITONEAL DIALYSIS</drugdosageform>
        <drugadministrationroute>033</drugadministrationroute>
        <drugindication>PERITONEAL DIALYSIS</drugindication>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>10044755</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140328</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140612</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-009507513-1403USA012625</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>MERCK</duplicatesource>
      <duplicatenumb>US-009507513-1403USA012625</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Device difficult to use</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Medical device complication</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Product quality issue</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>No adverse event</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>NEXPLANON</medicinalproduct>
        <drugauthorizationnumb>021529</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>IMPLANT</drugdosageform>
        <drugadministrationroute>059</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140326</drugstartdate>
        <actiondrug>4</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>NEXPLANON</medicinalproduct>
        <drugauthorizationnumb>021529</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>IMPLANT</drugdosageform>
        <drugadministrationroute>059</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140326</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20140326</drugenddate>
        <actiondrug>4</actiondrug>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>10042010</safetyreportid>
    <primarysourcecountry>AU</primarysourcecountry>
    <occurcountry>AU</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140327</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140414</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>AU-BRISTOL-MYERS SQUIBB COMPANY-20561478</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>BRISTOL MYERS SQUIBB</duplicatesource>
      <duplicatenumb>AU-BRISTOL-MYERS SQUIBB COMPANY-20561478</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>AU</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>63</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>73.7</patientweight>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Multi-organ failure</reactionmeddrapt>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>YERVOY</medicinalproduct>
        <drugauthorizationnumb>125377</drugauthorizationnumb>
        <drugdosagetext>221MG</drugdosagetext>
        <drugdosageform>INJECTION</drugdosageform>
        <drugindication>METASTATIC MALIGNANT MELANOMA</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140311</drugstartdate>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>10042797</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140327</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140617</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-GILEAD-2014-0097907</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>GILEAD</duplicatesource>
      <duplicatenumb>US-GILEAD-2014-0097907</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>71.682</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Ulcer haemorrhage</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Dyspnoea</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>LETAIRIS</medicinalproduct>
        <drugauthorizationnumb>022081</drugauthorizationnumb>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>10 MG, UNK</drugdosagetext>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>PULMONARY ARTERIAL HYPERTENSION</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20100728</drugstartdate>
        <actiondrug>4</actiondrug>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>WARFARIN</medicinalproduct>
        <drugrecurreadministration>3</drugrecurreadministration>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>LEVOTHYROX</medicinalproduct>
        <drugrecurreadministration>3</drugrecurreadministration>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>10042046</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20141212</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20140327</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20140414</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-GILEAD-2014-0097628</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>GILEAD</duplicatesource>
      <duplicatenumb>US-GILEAD-2014-0097628</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use </senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>34</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Genotype drug resistance test positive</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>17.0</reactionmeddraversionpt>
        <reactionmeddrapt>Virologic failure</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE</medicinalproduct>
        <drugbatchnumb> UNKNOWN</drugbatchnumb>
        <drugauthorizationnumb>021937</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>TABLET</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>HIV INFECTION</drugindication>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>201401</drugenddate>
        <actiondrug>1</actiondrug>
      </drug>
    </patient>
  </safetyreport>
</ichicsr>
